Latest News

Asbestos Awareness Month 1-30 November

‘Get to kNOw Asbestos this November’ The Asbestos Awareness Campaign aims to educate Australian about the dangers of asbestos in and around homes because Australia has one of the highest rates of asbestos-related diseases in the world. With asbestos-related diseases continuing to increase among Australians as a direct result of…

Read More
ADSS Symposium

ADSS Symposium 2016 Asbestos Related Diseases Here and Now

Professor Nico van Zandwijk was invited by the Asbestos Disease Support Society (adss) to present at the 2016 Symposium on Asbestos related diseases Here and Now in Brisbane on the 19th October 2016. Professor van Zandwijk spoke about the latest developments in mesothelioma treatment and research to audience of 200.…

Read More
Prof Ken Takahashi

ADRF Appoints New ADRI Director

The Board of the Asbestos Diseases Research Foundation (ADRF) is pleased to announce that Prof Ken Takahashi has been appointed as the new ADRI Director. He will take over from Prof Nico van Zandwijk – the Institute’s inaugural Director who has held the position since 2008 – in February of…

Read More

New article on TargomiRs

ADRI scientists and collaborators have published a special report on the clinical development of their microRNA-based treatment for mesothelioma. This report describes microRNA replacement therapy for cancer and the concept behind TargomiRs in the MesomiR-1 trial. It appears in the journal Epigenomics and can be found here

Read More

Latest biomarker research published

ADRI scientists have recently published an article in the British Journal of Cancer describing work on a blood biomarker for malignant pleural mesothelioma. It focuses on fibulin-3, a protein secreted by mesothelioma cells into the blood of patients. See here for a link to the paper.

Read More

New microRNA research paper published

A paper by ADRI scientists describing the role of a potential suppressor microRNA in malignant pleural mesothelioma biology has been published in the journal Oncotarget. Please see here for a link to the article.

Read More

Early results from MesomiR 1 trial published

The first results from the MesomiR 1 trial, a phase I clinical trial of a targeted delivery of a microRNA-based therapy, were published yesterday in the American Journal of Respiratory and Critical Care Medicine The trial is a collaboration between ADRI, the Sydney-based biotech company EnGeneIC Ltd and three hospitals…

Read More

Prof Nico van Zandwijk wins inaugural Dr J Stumphius Recognition Award

The Dr. J. Stumphius Recognition Award, sponsored by Shield Group International, was awarded to Prof. Nico van Zandwijk (ADRI) for his groundbreaking discovery in treating the asbestos cancer called mesothelioma, providing hope and saving lives of untold many people. The award, showing a glass plate on a bronze base, signifying…

Read More

ADRI Scientist awarded PhD scholarship

Marissa Williams, a Research Assistant at ADRI, was recently awarded a full PhD scholarship from Sydney Catalyst to support her PhD studies at The University of Sydney. This highly competitive and sought after award will allow Marissa to embark on PhD studies, putting to use the experience she has gained…

Read More

ADRI publishes new research

The team at ADRI recently had their work on the use of a tumour microRNA signature to predict outcomes in malignant pleural mesothelioma patients accepted for publication in the journal Molecular Oncology. See the article here

Read More